CNB1 Stock Overview
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology and pharmaceutical and biotechnology products in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Fortress Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.13 |
| 52 Week High | US$15.04 |
| 52 Week Low | US$3.66 |
| Beta | 2.04 |
| 1 Month Change | 0% |
| 3 Month Change | -3.03% |
| 1 Year Change | -63.88% |
| 3 Year Change | -89.65% |
| 5 Year Change | -73.00% |
| Change since IPO | -96.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| CNB1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | -1.7% |
| 1Y | -63.9% | -15.7% | 1.4% |
Return vs Industry: CNB1 underperformed the German Biotechs industry which returned -25.2% over the past year.
Return vs Market: CNB1 underperformed the German Market which returned 3.4% over the past year.
Price Volatility
| CNB1 volatility | |
|---|---|
| CNB1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CNB1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CNB1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 187 | Lindsay Rosenwald | www.fortressbiotech.com |
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children.
Fortress Biotech, Inc. Fundamentals Summary
| CNB1 fundamental statistics | |
|---|---|
| Market cap | €40.65m |
| Earnings (TTM) | -€71.57m |
| Revenue (TTM) | €56.64m |
0.7x
P/S Ratio-0.6x
P/E RatioIs CNB1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNB1 income statement (TTM) | |
|---|---|
| Revenue | US$61.97m |
| Cost of Revenue | US$155.48m |
| Gross Profit | -US$93.51m |
| Other Expenses | -US$15.20m |
| Earnings | -US$78.31m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.26 |
| Gross Margin | -150.89% |
| Net Profit Margin | -126.36% |
| Debt/Equity Ratio | -397.1% |
How did CNB1 perform over the long term?
See historical performance and comparison